Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression

International Journal of Oncology

Volumn 44, Issue 5, 2014, Pages 1736-1744

  Steffensen, Karina Dahl ^a,c   Smoter, Marta ^b   Waldstrøm, Marianne ^a   Grala, Bartłomiej ^b   Bodnar, Lubomir ^b   Stec, Rafał ^b   Szczylik, Cezary ^b   Jakobsen, Anders ^a,c  

^a LILLEBAELT HOSPITAL   (Denmark)

^b MILITARY INSTITUTE OF MEDICINE   (Poland)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

ERCC1; Ovarian cancer; Platinum resistance; Tau

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PACLITAXEL; TAU PROTEIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DNA REPAIR; DRUG SENSITIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROTUBULE; OVARY CARCINOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; TAU PROTEINS; TREATMENT OUTCOME;

EID: 84899078719     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2311     Document Type: Article

References (30)

1. Ozols RF: Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 33: S3-S11, 2006.
2. Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007. (Pubitemid 46137553)
3. Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535-1542, 1998.
4. Díaz-Padilla I and Poveda A: DNA repair-based mechanisms of platinum resistance in epithelial ovarian cancer: from bench to bedside. Clin Ovarian Cancer 3: 29-35, 2010.
5. Dabholkar M, Bradshaw L, Parker RJ, Gill I, Bostick-Bruton F, Muggia FM and Reed E: Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro. Environ Health Perspect 98: 53-59, 1992. (Pubitemid 23061782)
6. Reed E: Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24: 331-344, 1998.
7. De S, I, McHugh PJ, Clingen PH and Hartley JA: Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 20: 7980-7990, 2000.
8. Li Q, Yu JJ, Mu C, et al: Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 20: 645-652, 2000. (Pubitemid 30240614)
9. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C and Reed E: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84: 1512-1517, 1992.
10. Steffensen KD, Waldstrom M, Jeppesen U, Brandslund I and Jakobsen A: Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer. Int J Gynecol Cancer 18: 702-710, 2007.
11. Steffensen KD, Waldstrom M and Jakobsen A: The Relationship of Platinum Resistance and ERCC1 Protein Expression in Epithelial Ovarian Cancer. Int J Gynecol Cancer 19: 820-825, 2009.
12. Jiang J, Liang X, Zhou X, Huang R, Chu Z and Zhan Q: ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep 39: 6933-6942, 2012.
13. Hubner RA, Riley RD, Billingham LJ and Popat S: Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS One 6: e25164, 2011.
14. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006. (Pubitemid 44343542)
15. Kar S, Fan J, Smith MJ, Goedert M and Amos LA: Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J 22: 70-77, 2003. (Pubitemid 36091270)
16. Andre F, Hatzis C, Anderson K, et al: Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 13: 2061-2067, 2007. (Pubitemid 46649873)
17. Rouzier R, Rajan R, Wagner P, et al: Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102: 8315-8320, 2005. (Pubitemid 40800086)
18. Tanaka S, Nohara T, Iwamoto M, Sumiyoshi K, Kimura K, Takahashi Y and Tanigawa N: Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer. Cancer Chemother Pharmacol 64: 341-346, 2009.
19. Shao YY, Kuo KT, Hu FC, et al: Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. Jpn J Clin Oncol 40: 286-293, 2010.
20. Mimori K, Sadanaga N, Yoshikawa Y, et al: Reduced tau expression in gastric cancer can identify candidates for successful Paclitaxel treatment. Br J Cancer 94: 1894-1897, 2006. (Pubitemid 43882581)
21. Pusztai L, Jeong JH, Gong Y, et al: Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol 27: 4287-4292, 2009.
22. Pentheroudakis G, Kalogeras KT, Wirtz RM, et al: Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat 116: 131-143, 2009.
23. Smoter M, Bodnar L, Grala B, Stec R, Zieniuk K, Kozlowski W and Szczylik C: Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/ platinum first-line chemotherapy. J Exp Clin Cancer Res 32: 25, 2013.
24. Kurman RJ and Shih I: Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27: 151-160, 2008. (Pubitemid 351450677)
25. Shih I and Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164: 1511-1518, 2004. (Pubitemid 38529752)
26. Steffensen KD, Waldstrom M, Grove A, Lund B, Pallisgard N and Jakobsen A: Improved classification of epithelial ovarian cancer: results of 3 Danish cohorts. Int J Gynecol Cancer 21: 1592-1600, 2011.
27. Steffensen KD, Waldstrom M and Jakobsen A: DNA-repair ERCC1 gene polymorphisms in epithelial ovarian cancer and relation to platinum resistance and survival. J Cancer Ther 2: 140-147, 2011.
28. Rubatt JM, Darcy KM, Tian C, et al: Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a gynecologic oncology group study. Gynecol Oncol 125: 421-426, 2012.
29. Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD and Niedernhofer LJ: Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue. Cancer Res 69: 6831-6838, 2009.
30. Olaussen KA and Soria JC: Validation of ERCC1-XPF immunodetection - letter. Cancer Res 70: 3851-3852, 2010.